ArticleArthritis & rheumatology (Hoboken, N.J.)2015
Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.Arthritis care & research · 2019Guideline
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.Arthritis & rheumatology (Hoboken, N.J.) · 2019Guideline
- The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis.Pediatric rheumatology online journal · 2019Pooled it
- How Safe Are Biological Agents in Pediatric Rheumatology?Turkish archives of pediatrics · 2024Article
- Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis.Rheumatology (Oxford, England) · 2023Article
- Serine, N-acetylaspartate differentiate adolescents with juvenile idiopathic arthritis compared with healthy controls: a metabolomics cross-sectional study.Pediatric rheumatology online journal · 2022Article
- Are infections in children with juvenile idiopathic arthritis more frequent than in healthy children? A prospective multicenter observational study.Frontiers in pediatrics · 2022Article
- Targeted inhibition of GRK2 kinase domain by CP-25 to reverse fibroblast-like synoviocytes dysfunction and improve collagen-induced arthritis in rats.Acta pharmaceutica Sinica. B · 2021Article
- Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.Arthritis research & therapy · 2020Article
- Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.Clinical medicine (London, England) · 2020Article
- COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.Pediatric rheumatology online journal · 2020Review
- Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study.The Lancet. Rheumatology · 2020Article
- Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.Clinical rheumatology · 2020Article
- [Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs].Zeitschrift fur Rheumatologie · 2019Review
- Paeoniflorin-6'-O-benzene sulfonate alleviates collagen-induced arthritis in mice by downregulating BAFF-TRAF2-NF-κB signaling: comparison with biological agents.Acta pharmacologica Sinica · 2019Article
- The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.Clinical rheumatology · 2019Article
- Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis.Rheumatology (Oxford, England) · 2019Article
- Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.Rheumatology (Oxford, England) · 2019Observational
- Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.Rheumatology (Oxford, England) · 2019Article
- Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.Arthritis research & therapy · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveThe association between anti-tumor necrosis factor therapy and increased rates of infection is widely documented in adults with rheumatoid arthritis. Findings in children with juvenile idiopathic arthritis (JIA) have been less well documented. The aims of this analysis were to compare the rates of medically significant infections (MSIs) in children with JIA treated with etanercept (ETN) versus methotrexate (MTX) and to compare the rates between combination therapy with ETN plus MTX and monotherapy with ETN.
methodsA total of 852 ETN-treated children and 260 MTX-treated children had been recruited to the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN). MSIs included infections that resulted in death or hospitalization or were deemed medically significant by the clinician. This on-drug analysis followed the patients until the first MSI, treatment discontinuation, the last followup, or death. Cox proportional hazards models, which were adjusted using propensity deciles, were used to compare rates of MSI between cohorts. Sensitivity analyses were conducted specifically with regard to serious infections (SIs), which were defined as those requiring hospitalization or treatment with intravenous antibiotics/antivirals.
resultsThe ETN-treated cohort was older and had a longer disease duration, but the disease activity was similar between the cohorts. A total of 133 first MSIs were reported (109 with ETN and 24 with MTX). Patients receiving ETN had higher rates of MSI than did the controls (propensity decile adjusted hazard ratio 2.13 [95% confidence interval 1.22-3.74]). The risk of MSI was higher whether patients were receiving combination or monotherapy. Sensitivity analysis showed no between-group difference in the rate of SIs, which were much less common.
conclusionETN therapy is associated with an increased risk of MSI; however, this increased risk disappears when considering only SIs, which suggests that either there were differences in the severity of infections and/or there was a possible reporting bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.